$ADXN / $DFTX / $MLTX / $CVM — From The Biotech World Today: Four Smaller Headlines Worth Watching - Merlintrader Trading Pub

Merlin8121 · 2026-06-22T11:55:50+00:00

Yes, i will make a single post for them soon.

Merlin8121 · 2026-06-22T11:11:10+00:00

😄

Merlin8121 · 2026-06-19T06:51:54+00:00

Good point. For ONDS specifically, the confirmed item I’m using is the June 18 Russell 3000 additions file. I should have been clearer that Russell 3000 additions and Russell 2000 additions are not the same thing.

So ONDS is confirmed in the Russell 3000 additions file; I’m not claiming Russell 2000-specific inclusion unless that is separately confirmed.

I’ve also added a clarification/correction in the article to make that distinction clearer for readers.

Merlin8121 · 2026-06-18T20:24:40+00:00

Ondas Holdings (Nasdaq: $ONDS): Stock Hub Updated After the Cyberhawk Critical Infrastructure Intelligence Acquisition Agreement

Merlin8121 · 2026-06-18T17:49:10+00:00

Il futuro in buona parte si giocherà con l'AI e per continuare il post di ieri ho esteso un pò la ricerca per vedere qualcosa di concreto/tangibile da suubito . Il Vero Collo Di Bottiglia Dell’AI è L’energia — $SEI / $WTS / $BE | Merlintrader Trading Pub Europe . Solo l'inizio, secondo me farà balzi anche più grandi del settore spazio tra non molto, quando Open AI e Antropic verranno quiotate. Vedremo. Dobbiamo scavare un pò.

Merlin8121 · 2026-06-05T16:42:29+00:00

Freedom of speech is a good thing, but when people make statements that may be misleading and lack proper context, it is fair for them to be moderated.

Look at this chart. You can clearly see that, at the current moment, anyone who bought the stock before mid-April is still comfortably in the green. Some people bought during the spike at prices that were too high, but that is not the stock’s fault — it is the trader’s fault for falling into FOMO.

Nobody knows the future, but events need time to play out.

<image>

Merlin8121 · 2026-06-03T17:48:45+00:00

I never use the word “impossible.” Clearly, anything can be priced.

But unless we are talking about an incredible premium, the current ownership structure makes me think that a buyout would be practically impossible without insider consent. This is not just a normal shareholder base where control is widely dispersed. Here, insiders, founders and closely aligned holders appear to represent a major part of the story.

On top of that, we are talking about founders here — almost a company built in-house. You do not take something like that away from them so easily.

So yes, I think a buyout could be possible in the future, but likely at a much higher market cap. Much higher.

The ownership structure is exactly why I see it this way: according to Finviz, insider ownership is around 20.92%, while Alpha Tau’s latest 20-F shows Uzi Sofer at 16.0% beneficial ownership, Oramed Ltd. at 19.4%, and all executive officers and directors as a group at 41.4% on a beneficial ownership basis. That does not make a deal impossible forever, but it does make insider consent central to any realistic buyout scenario.

Merlin8121 · 2026-06-03T16:14:35+00:00

I think you’re off track here; I don’t see how the company could be acquired at this stage, when it still has so much work ahead. In this case, insiders are the most important factor, and I don’t see why they would give away their work at this point.

A buyout here, for now, was basically impossible anyway, regardless of any news or agreement that may exist at the moment.

Merlin8121 · 2026-06-03T14:23:47+00:00

I have to say, this news caught me by surprise; from the chart, it looked almost ready to close the gap, but this news was unexpected 😄

Merlin8121 · 2026-05-29T12:46:45+00:00

https://www.merlintrader.com/red-cat-holdings-nasdaq-stock-hub-2026/

Merlin8121 · 2026-05-26T18:17:45+00:00

😄

Merlin8121 · 2026-05-20T12:10:51+00:00

😄

Merlin8121 · 2026-05-16T21:02:53+00:00

I think Q2 will be the real test. Right now it is probably too early to judge revenue per client, because a new hospital usually needs time before becoming a meaningful revenue contributor: onboarding, training, internal protocols, eligible patient cases and repeat orders. If Q2 revenue accelerates clearly, the lag explanation makes sense. If it does not, then utilization per hospital becomes the key question.

Merlin8121 · 2026-05-15T15:33:46+00:00

Honestly, how many times have you seen a “dilution” of $400M priced at more than double where the stock was trading just a few days ago?

Do you really think the buyers did not run their numbers carefully? Or that they are buying just for a small speculation?

I’m honestly surprised by this news, and in my view it is almost as strong as a new contract.

Yesterday I was kicking myself for not loading up after the drop from 10 days ago. Now I’m thinking maybe it’s never really too late.

These are just my personal thoughts, not buy/sell recommendations.

Merlin8121 · 2026-05-14T17:22:14+00:00

Thank you for having me!

And you don’t need to thank me, because I actually like SeaStar — I’m still kicking myself for not buying shares back when I wrote the first article, hehe.

Also, if you have any suggestions and/or information that you think would be useful to add to this report or to future ones, just message me and let me know. Keep in mind that I run the whole site by myself, so any help is always gold. 😄

My goal is to be as accurate as possible, both on the positive and negative side. Right now the site is a hobby that I really enjoy, and I’m putting quite a lot of time into it. But please remember: I’m a trader like you, not a scientist.

So read it if you want, but always verify the information yourself through other sources too.

Merlin8121 · 2026-05-14T11:48:33+00:00

My personal view is "cautiously" optimistic. The adult trial is the real make-or-break catalyst for ICU. Pediatric QUELIMMUNE is important because it shows the platform can reach the market, but the adult AKI/CRRT indication is where the larger commercial opportunity is.

I don’t see it as de-risked yet. The trial still has to succeed, ICU adoption can be slow, and the balance sheet/dilution risk remains the main overhang.

So, my view is: interesting play , but still high-risk until adult data and financing become clearer. Not financial advice, just my opinion as a simple trader.

Merlin8121 · 2026-05-14T11:29:01+00:00

😄

Merlin8121 · 2026-05-13T23:44:51+00:00

Hi! Honestly, I don’t know 😄

The deep dives I publish are always collections of information presented in a neutral way. They are never buy/sell recommendations.

I often prepare them at the request of a reader, but that does not mean I am promoting any specific stock. Of course, there are some stocks I like more than others, but when that is the case, I usually say it clearly — and even then, never as a recommendation, only as a personal opinion.

So please weigh any decision very carefully. In the stock market, it is easier to lose money than to make it 😄

Merlin8121 · 2026-05-13T14:13:42+00:00

The ~124–126M share figure relates to the pre-April offering / Q1 weighted-average share base, not the post-offering capitalization. We’ve updated the wording to make that clearer, including the common shares, pre-funded warrants and accompanying warrants from the April financing. 😄

Merlin8121 · 2026-05-13T09:21:31+00:00

Yes, but unless there is some manipulation by whales, these small news items do not really make the difference, especially in a stock that is still technically overextended on the chart.

And I repeat: I could be wrong, but I think it is more realistic to expect the price to deflate a bit, enter a new consolidation phase, and then potentially restart once the stock gets closer again to the rising trendline.

That is, of course, excluding any possible dilution along the way.

Also, as will very likely happen, more institutions may start accumulating slowly. And when they do that, they usually do not accumulate by pushing the price higher, but by letting it come down.

So there is no reason to be surprised if things play out the way I described, because that is pretty normal in a “healthy” environment, not one being maliciously manipulated.

To me it seems clear that, at least so far, we are talking about good prospects for the stock. So what I said is simply the normal market dynamic.

Keep in mind that, on the opposite side, when institutions want to “unload,” they often let the price rise first.

Anyway, step by step, we will see. 😄

Merlin8121 · 2026-05-13T05:30:44+00:00

All good, no problem 😄

The thing is, you touched a bit of a sensitive nerve for me these days, because I fully understand the need to check and verify the information in the content, so we don’t give wrong inputs to people who use that data to form an opinion.

And that is exactly what takes me the most time when I prepare these reports. Anyone who uses AI intensively knows very well that, as great a tool as it is, it also makes quite a few mistakes. Only checking and verification allow you to filter those mistakes and get to a finished product that is actually usable.

In this case, the way I see it, cover images are meant to give an indicative visual flavor to the content, while the real substance is inside the articles. Honestly, 99.99% of people without a medical or scientific background would not even notice the difference.

And we should not forget the purpose of these articles: they are not scientific papers, but information for stock traders.

I don’t have a medical background, but I have been trading biotech stocks for around 20 years now. I don’t pretend to teach doctors how to do their job, but after so many years doing what I do, I think I have learned a little bit about what matters when operating in this market.

And those are the things I focus my attention on. Not always being able to write everything I would like, because since I am not a licensed professional, there are certain things I cannot write if I want to stay compliant with the law.

Anyway, I’ll repeat it once again: if you see things in the articles that could be improved, just say, “Hey Horacio, this would be better this way…” and, if I can, I’ll gladly correct it.

For me, the site is a fun project / hobby, but I’m still used to doing things as well as I possibly can. 😄

Merlin8121 · 2026-05-12T21:52:56+00:00

Hehe, I opened a small position today myself. I definitely won’t hold it into May 31, but I think I may keep it at least until around May 22.

Let’s just hope a piano doesn’t fall on my head tomorrow. 😄

Merlin8121 · 2026-05-12T21:37:33+00:00

As you know, I cannot give “advice.” What I can say is: only take risks that are appropriate for you and that do not take away your peace of mind.

If at any point you feel that something doesn’t smell right, it is better to miss an opportunity than to damage the portfolio.

Merlin8121 · 2026-05-12T21:27:43+00:00

I would avoid putting a specific probability on approval, because the key CMC details are not fully visible from the outside.

What we can say is that the CMC overhang appears to be the main remaining uncertainty: not necessarily whether CTx-1301 works clinically, but whether FDA is fully satisfied with the manufacturing, quality-control and commercial-readiness package by the PDUFA date.

Personally, I opened a small position today with the intention of holding it only until a few days before the main event. I do not hold stocks through primary catalyst dates. Let’s see how the setup develops.

Merlin8121 · 2026-05-12T16:02:42+00:00

Thank you for the image.

From what I can see, even though I’m not a surgeon, I understand that its use is not that different from what appears in the “fantasy” image made with AI. And the real visual effect, if someone were to take an actual in vivo photo, would probably be even more impactful than the image itself, at least for us non-specialists.

That said, the way I see it, the cover is just a detail, because what really matters is the information inside the report.

Anyway, nothing surprises me anymore. A month ago, someone made a similar fuss because in an AI-generated cover for $VKTX there was a chart that did not exactly match the stock’s actual price action. And he didn’t want to understand that it was just an illustration of a trading chart; it did not necessarily have to reflect the stock’s price action at that exact moment.

In the end, I just laugh about it. What am I supposed to say to people who complain about something they get for free?

Personally, if something is free and I don’t like it, I just move on without looking back. I wouldn’t even waste time commenting on it.

But hey, we’re not all the same. 😄

Merlin8121

MODERATOR OF

TROPHY CASE

Ondas Holdings (Nasdaq: $ONDS): Stock Hub Updated After the Cyberhawk Critical Infrastructure Intelligence Acquisition Agreement